Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2023

Note 10 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Accrued clinical and development expenditure	$	17,811	$	16,749
Accrued employee expenses		4,780		8,232
Other accrued expenditure		7,850		4,079
Other		2,769		2,155
	$	33,210	$	31,215